TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02716779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ribavirin matching placebo orally (PO) twice daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Study: NCT03488797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised web- and home-based exercise intervention
Description: * The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)
Study: NCT00004067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: herceptin
Description: 4 mg/kg loading dose then 2 mg/kg weekly for 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: 60 mg/m2 IV push every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adriamycin
Description: 60 mg/m2 IV push every 21 days for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxol
Description: 175 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxol
Description: 175 mg/m2 IV every 21 days for 4 cycles
Study: NCT00320788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Description: Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
Study: NCT04396132

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Subjective Visual Vertical with Virtual SVV instrument
Description: The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
Study: NCT05986292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 ISA
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 ISA
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 ISA
Description: Administered intravenously (IV)
Study: NCT00959283

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05986292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210 ISA
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral
Description: Placebo administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV
Study: NCT04483102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Declined liver in Normothermic Machine Perfusion (NMP)
Description: The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cold preservation of liver
Description: The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.
Study: NCT02156739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Disodium
Description: Given IV
Study: NCT02316002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02683447

Intervention type: OTHER
Intervention: CRM Simulation
Description: Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
Study: NCT01886872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT01565109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Cisplatine - 5FU
Description: 2 cycles of Docetaxel - Cisplatine - 5 FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation of 45 Grays on 5 weeks
Description: Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
Study: NCT03311841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg single dose (two 300 mg capsules) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg single dose (two 300 mg capsules) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg single dose (two 300 mg capsules) administered orally
Study: NCT02480881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: Investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive
Description: Subject's existing combination OC tablet containing EE and progestin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30
Description: OC containing EE and norethindrone acetate (NEA)
Study: NCT01941784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo health education program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo health education program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive follow-up phone calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00640419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
Study: NCT00725907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGRF
Description: injection of 6cc into injured area

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Description: injection of 6cc into injured area
Study: NCT02077309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00074815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serotonin reuptake inhibitors management
Description: Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors management
Description: Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors management
Description: Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.
Study: NCT03283878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2.
Study: NCT00074815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy by a psychologist
Description: CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
Study: NCT03199651

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of tumor tissue and blood sample for repository

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor tissue and blood sample for AGIT/DS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Undergo medical record abstraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical record abstraction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Undergo usual care or NCCN-driven CTC/DS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Undergo usual care or NCCN-driven CTC/DS
Study: NCT03913481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Description: In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Best available treatment without ANH
Study: NCT01272037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00074815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional cognitive behavioral therapy by a psychiatrist
Description: The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy.
Study: NCT03247088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study: NCT01272037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 12/1/12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 12/1/12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT03247088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01272037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO